Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Rhea-AI Summary
Bicara Therapeutics (Nasdaq: BCAX) will report first quarter 2026 financial results and business updates before the market opens on May 11, 2026. A conference call will follow at 8:30 a.m. ET, with a live webcast and a replay available for 30 days.
Registration is required for dial-in details and a unique PIN; the webcast is available in the Investors & Events section on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – BCAX
In the May 4 session, BCAX gained 4.85%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Earnings date notice | Neutral | -0.1% | Scheduled Q4 and full-year 2025 results call with webcast and replay details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For prior earnings date announcements, BCAX saw only a minimal move, averaging about -0.11%, suggesting these scheduling updates have historically been low-volatility catalysts.
Recent BCAX news shows a sequence of capital formation and development progress. In late February 2026, the company priced and then closed an oversubscribed equity and pre-funded warrant offering, raising gross proceeds of about $150–172.5M. On March 30, 2026, Bicara reported Q4 and full-year 2025 results, highlighting selection of a 1500mg dose, initiation of Phase 3 FORTIFI-HN01 with interim analysis expected mid-2027, and a cash position of $414.8M plus $161.8M raised in Q1 2026. Today’s release continues the pattern of scheduled financial updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Contacts:
Investors
Rachel Frank
IR@bicara.com
Media
Tim Palmer
tim.palmer@bicara.com
